Structure-based design of therapeutics to control hemostasis

Area of Science:

• Biomaterials Science
• Trauma Care
• Hemostasis

Background:

• Hemorrhage is a leading cause of death, particularly in pre-hospital trauma settings.
• Current treatments like transfused blood products face logistical challenges in remote and military environments.
• Existing limitations necessitate the development of improved hemostatic agents with extended shelf life and portability.

Purpose of the Study:

• To review material-based approaches for designing novel hemostatic agents.
• To address limitations of current blood products for pre-hospital bleeding management.
• To explore strategies for enhancing both bleeding cessation and wound healing.

Main Methods:

• Review of literature on material design for hemostatic applications.
• Analysis of strategies for incorporating active components into hemostatic materials.
• Consideration of patient-specific factors in material development.

Main Results:

• Material design offers a promising avenue for developing advanced hemostatic agents.
• Incorporation of transglutaminases, growth factors, cellular components, or inorganic molecules can enhance material functionality.
• Tailoring therapies to specific patient populations (e.g., by sex or age) is crucial for next-generation hemostats.

Conclusions:

• Material-based strategies hold significant potential for creating effective pre-hospital hemostatic agents.
• Future development should focus on improving shelf life, portability, scalability, cost, and safety.
• Personalized approaches considering patient-specific factors will advance hemostatic material technology.